Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Godavari Drugs Ltd?

Godavari Drugs Ltd is trading at 92.80 as of 21 April 2026, with a FY2026-2027 high of 115 and low of 69.7. The stock is currently in the middle of its 52-week range. Market cap stands at 94.0 Cr..

Q: Is Godavari Drugs Ltd financially healthy?

Key indicators: ROCE of 10.1 % is moderate. Dividend yield is 0.00 %.

Q: Is Godavari Drugs Ltd profitable and how is the profit trend?

Godavari Drugs Ltd reported a net profit of 4 Cr in Mar 2025 on revenue of 113 Cr. Compared to 5 Cr in Mar 2022, the net profit shows a declining trend.

Fair Value

₹139.78Undervalued by 50.63%vs CMP ₹92.80

P/E (26.8) × ROE (10.6%) × BV (₹60.30) × DY (2.00%)

₹98.65Fairly Valued by 6.30%vs CMP ₹92.80

MoS: +5.9% (Thin)Confidence: 50/100 (Moderate)Models: 2 Under, 5 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹130.27	29%	Under (+40.4%)
Graham Number	Earnings	₹81.54	21%	Over (-12.1%)
Net Asset Value	Assets	₹44.81	9%	Over (-51.7%)
EV/EBITDA	Enterprise	₹39.72	12%	Over (-57.2%)
Earnings Yield	Earnings	₹49.00	9%	Over (-47.2%)
ROCE Capital	Returns	₹217.73	12%	Under (+134.6%)
Revenue Multiple	Revenue	₹55.95	7%	Over (-39.7%)
Consensus (7 models)		₹98.65	100%	Fairly Valued

Key Drivers: Wide model spread (₹40–₹218) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -6.8%

*Investments are subject to market risks

Analyst Summary

Godavari Drugs Ltd operates in the Pharmaceuticals segment, NSE: GODAVARI | BSE: 530317, current market price is ₹92.80, market cap is 94.0 Cr.. At a glance, stock P/E is 26.8, ROE is 10.6 %, ROCE is 10.1 %, book value is 60.3, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹98.65, which is about 6.3% above the current price, so the page currently reads as potentially undervalued rather than fully priced. On operating trend, latest reported sales are about ₹113 Cr versus the prior period change of -27.7%, while latest net profit is about ₹4 Cr with a prior-period change of -21.1%. This analysis page also carries profit and loss, shareholding pattern, ratio panels data, which improves the depth of the template beyond a thin price-only snapshot. The 52-week range shown on this page is 115/69.7, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisGodavari Drugs Ltd. is a Public Limited Listed company incorporated on 02/12/1987 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1987PLC008016 and registration number is 008016. Currently Company is involv…

This summary is generated from the stock page data available for Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Godavari Drugs Ltd scores 48/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health46/100 · Moderate

ROCE 10.1% AverageROE 10.6% AverageD/E 1.15 High debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent

Smart Money50/100 · Moderate

Promoter holding at 52.6% Stable

Earnings Quality65/100 · Strong

OPM expanding (7% → 9%) Improving

Quarterly Momentum25/100 · Weak

Revenue (4Q): -22% YoY DecliningProfit (4Q): -40% YoY Declining

Industry Rank55/100 · Moderate

P/E 26.8 vs industry 53.8 Cheaper than peersROCE 10.1% vs industry 16.4% Average3Y sales CAGR: -11% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:42 am

Market Cap	94.0 Cr.
Current Price	92.8
Intrinsic Value	₹98.65
High / Low	115/69.7
Stock P/E	26.8
Book Value	60.3
Dividend Yield	0.00 %
ROCE	10.1 %
ROE	10.6 %
Face Value	10.0
PEG Ratio	-3.94

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Godavari Drugs Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Godavari Drugs Ltd	94.0 Cr.	92.8	115/69.7	26.8	60.3	0.00 %	10.1 %	10.6 %	10.0
Aarti Pharmalabs Ltd	5,757 Cr.	635	972/557	26.7	226	0.79 %	17.4 %	14.5 %	5.00
Morepen Laboratories Ltd	2,038 Cr.	37.2	70.5/33.0	26.7	21.8	0.54 %	15.1 %	11.8 %	2.00
Fervent Synergies Ltd	91.3 Cr.	18.3	29.8/16.0	26.5	10.8	0.00 %	7.47 %	7.47 %	10.0
Procter & Gamble Health Ltd	7,983 Cr.	4,809	6,739/4,725	27.2	373	2.60 %	47.8 %	36.4 %	10.0
Industry Average	19,815.15 Cr	1,053.84		53.84	201.20	0.39%	16.35%	15.16%	6.10

All Competitor Stocks of Godavari Drugs Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	39.16	37.37	35.42	39.54	43.11	38.64	32.21	26.09	29.55	25.50	23.81	26.65	22.18
Expenses	36.89	34.69	33.17	36.47	39.59	34.17	28.98	23.19	26.97	22.39	20.91	24.65	19.71
Operating Profit	2.27	2.68	2.25	3.07	3.52	4.47	3.23	2.90	2.58	3.11	2.90	2.00	2.47
OPM %	5.80%	7.17%	6.35%	7.76%	8.17%	11.57%	10.03%	11.12%	8.73%	12.20%	12.18%	7.50%	11.14%
Other Income	0.30	0.39	0.45	0.00	-0.01	0.08	0.77	0.01	0.10	0.11	0.01	0.64	0.27
Interest	1.10	1.03	1.11	1.30	1.27	1.23	1.44	1.08	1.11	1.11	1.00	0.91	1.11
Depreciation	0.51	0.50	0.47	0.49	0.50	0.53	0.55	0.58	0.64	0.67	0.60	0.60	0.61
Profit before tax	0.96	1.54	1.12	1.28	1.74	2.79	2.01	1.25	0.93	1.44	1.31	1.13	1.02
Tax %	30.21%	13.64%	27.68%	32.81%	29.89%	4.66%	18.91%	12.80%	16.13%	38.19%	19.85%	10.62%	25.49%
Net Profit	0.67	1.33	0.81	0.86	1.22	2.66	1.63	1.09	0.77	0.89	1.04	1.00	0.76
EPS in Rs	0.89	1.77	1.08	1.14	1.62	3.53	2.16	1.45	1.02	1.18	1.38	1.33	1.01

Last Updated: March 3, 2026, 9:32 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 6:00 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	9.43	54.85	71.12	75.60	64.45	83.54	95.70	122.67	161.11	159.62	156.71	113.35	98.14
Expenses	7.59	49.07	66.63	70.38	60.41	78.06	89.67	112.83	149.82	149.69	143.40	101.53	87.66
Operating Profit	1.84	5.78	4.49	5.22	4.04	5.48	6.03	9.84	11.29	9.93	13.31	11.82	10.48
OPM %	19.51%	10.54%	6.31%	6.90%	6.27%	6.56%	6.30%	8.02%	7.01%	6.22%	8.49%	10.43%	10.68%
Other Income	0.12	0.30	0.19	0.80	0.68	0.24	0.33	0.41	0.28	0.88	0.53	0.98	1.03
Interest	0.21	0.67	1.88	2.51	2.42	2.89	2.91	3.32	2.85	3.93	4.92	4.73	4.13
Depreciation	1.05	0.68	0.63	0.81	0.99	1.09	1.16	1.22	1.70	1.94	1.99	2.45	2.48
Profit before tax	0.70	4.73	2.17	2.70	1.31	1.74	2.29	5.71	7.02	4.94	6.93	5.62	4.90
Tax %	-121.43%	23.04%	38.25%	32.96%	37.40%	31.03%	12.66%	27.67%	25.36%	23.28%	19.91%	22.24%
Net Profit	1.55	3.65	1.35	1.81	0.83	1.21	2.00	4.13	5.25	3.79	5.55	4.38	3.69
EPS in Rs	2.06	4.85	1.79	2.40	1.10	1.61	2.66	5.48	6.97	5.03	7.37	5.82	4.90
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	135.48%	-63.01%	34.07%	-54.14%	45.78%	65.29%	106.50%	27.12%	-27.81%	46.44%	-21.08%
Change in YoY Net Profit Growth (%)	0.00%	-198.50%	97.09%	-88.22%	99.93%	19.51%	41.21%	-79.38%	-54.93%	74.25%	-67.52%

Godavari Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	8%
5 Years:	3%
3 Years:	-11%
TTM:	-32%

Compounded Profit Growth
10 Years:	2%
5 Years:	17%
3 Years:	-6%
TTM:	-41%

Stock Price CAGR
10 Years:	4%
5 Years:	17%
3 Years:	7%
1 Year:	-41%

Return on Equity
10 Years:	13%
5 Years:	15%
3 Years:	13%
Last Year:	11%

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: March 3, 2026, 1:04 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53
Reserves	1.98	5.53	6.88	8.69	9.52	10.73	12.73	16.86	22.10	25.89	31.44	35.82	37.86
Borrowings	2.42	8.48	15.51	15.76	19.17	22.06	27.60	30.46	23.07	35.85	57.77	64.35	73.93
Other Liabilities	3.32	13.20	20.63	23.72	26.80	33.42	36.06	36.29	48.71	52.17	38.01	35.38	43.14
Total Liabilities	15.25	34.74	50.55	55.70	63.02	73.74	83.92	91.14	101.41	121.44	134.75	143.08	162.46
Fixed Assets	8.21	7.28	8.73	12.77	14.56	14.97	13.81	22.43	26.25	24.91	26.68	32.61	31.42
CWIP	0.00	0.42	1.20	0.12	0.97	2.05	8.93	0.76	0.49	9.08	18.32	29.95	40.88
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	7.04	27.04	40.62	42.81	47.49	56.72	61.18	67.95	74.67	87.45	89.75	80.52	90.16
Total Assets	15.25	34.74	50.55	55.70	63.02	73.74	83.92	91.14	101.41	121.44	134.75	143.08	162.46

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	2.24	-5.85	-4.53	5.15	3.82	3.71	6.24	1.33	11.23	13.22	18.41	11.20
Cash from Investing Activity +	-2.29	-0.20	-2.08	-2.97	-2.95	-2.34	-6.68	-1.25	-4.97	-8.64	-13.22	-19.51
Cash from Financing Activity +	0.03	6.07	6.99	-1.95	-0.14	-1.46	0.34	0.13	-5.62	-3.77	-5.65	8.07
Net Cash Flow	-0.02	0.01	0.39	0.23	0.73	-0.09	-0.10	0.21	0.64	0.81	-0.46	-0.25
Free Cash Flow	-0.05	-6.05	-6.61	1.38	0.20	1.13	-0.65	-0.34	5.98	4.07	5.40	-8.80
CFO/OP	122%	-101%	-101%	108%	109%	73%	108%	26%	110%	143%	146%	105%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-0.58	-2.70	-11.02	-10.54	-15.13	-16.58	-21.57	-20.62	-11.78	-25.92	-44.46	-52.53

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	20	87	126	117	152	148	137	134	126	132	138	136
Inventory Days	973	84	67	70	100	93	84	55	28	57	62	125
Days Payable	179	79	108	124	171	171	144	112	121	132	96	128
Cash Conversion Cycle	814	92	85	63	81	70	78	78	33	58	105	133
Working Capital Days	120	63	44	40	47	38	31	46	32	23	9	11
ROCE %	8%	32%	16%	17%	11%	12%	12%	18%	18%	14%	14%	10%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	53.12%	53.16%	53.16%	53.16%	53.16%	53.16%	52.63%	52.63%	52.63%	52.63%	52.61%	52.61%
DIIs	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%	0.50%
Public	46.39%	46.34%	46.33%	46.35%	46.34%	46.34%	46.87%	46.87%	46.87%	46.87%	46.90%	46.89%
No. of Shareholders	6,555	6,561	7,019	6,894	7,005	7,044	7,709	7,915	7,881	7,828	7,720	7,483

Shareholding Pattern Chart

No. of Shareholders

Godavari Drugs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE / ROE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	5.82	7.37	5.03	6.97	5.48
Diluted EPS (Rs.)	5.82	7.37	5.03	6.97	5.48
Cash EPS (Rs.)	9.07	10.02	7.61	9.22	7.11
Book Value[Excl.RevalReserv]/Share (Rs.)	57.56	51.74	44.38	39.35	32.38
Book Value[Incl.RevalReserv]/Share (Rs.)	57.56	51.74	44.38	39.35	32.38
Revenue From Operations / Share (Rs.)	150.52	208.10	211.97	213.94	162.90
PBDIT / Share (Rs.)	17.00	18.49	14.04	15.36	13.59
PBIT / Share (Rs.)	13.75	15.84	11.46	13.11	11.97
PBT / Share (Rs.)	7.47	9.19	6.55	9.32	7.58
Net Profit / Share (Rs.)	5.82	7.37	5.03	6.96	5.48
PBDIT Margin (%)	11.29	8.88	6.62	7.17	8.34
PBIT Margin (%)	9.13	7.61	5.40	6.12	7.34
PBT Margin (%)	4.96	4.41	3.09	4.35	4.65
Net Profit Margin (%)	3.86	3.54	2.37	3.25	3.36
Return on Networth / Equity (%)	10.10	14.24	11.32	17.70	16.92
Return on Capital Employeed (%)	14.79	22.60	18.08	22.61	22.18
Return On Assets (%)	3.06	4.11	3.11	5.17	4.52
Long Term Debt / Equity (X)	0.55	0.28	0.35	0.39	0.59
Total Debt / Equity (X)	1.42	1.43	1.00	0.68	1.15
Asset Turnover Ratio (%)	0.81	1.22	1.43	1.67	1.40
Current Ratio (X)	1.08	1.08	1.18	1.29	1.34
Quick Ratio (X)	0.69	0.82	0.91	1.11	1.05
Inventory Turnover Ratio (X)	4.67	6.02	9.22	10.37	5.81
Interest Coverage Ratio (X)	2.71	2.83	2.69	4.06	3.09
Interest Coverage Ratio (Post Tax) (X)	1.93	2.15	1.91	2.84	2.25
Enterprise Value (Cr.)	125.12	123.00	87.45	67.32	60.89
EV / Net Operating Revenue (X)	1.10	0.78	0.54	0.41	0.49
EV / EBITDA (X)	9.77	8.83	8.27	5.82	5.95
MarketCap / Net Operating Revenue (X)	0.58	0.44	0.35	0.30	0.28
Price / BV (X)	1.52	1.80	1.71	1.66	1.41
Price / Net Operating Revenue (X)	0.58	0.44	0.35	0.30	0.28
EarningsYield	0.06	0.07	0.06	0.10	0.11

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Godavari Drugs Ltd. is a Public Limited Listed company incorporated on 02/12/1987 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1987PLC008016 and registration number is 008016. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company's Total Operating Revenue is Rs. 113.35 Cr. and Equity Capital is Rs. 7.53 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	1-8-303/34, Secunderabad Telangana 500003	Contact not found

Management
Name	Position Held
Mr. Ghanshyam Jaju	Chairman
Mr. Mukund Kakani	Managing Director
Mr. Mohit Jaju	WholeTime Director & CFO
Mr. Mahendra Bhalerao	Ind. Non-Executive Director
Mr. Dinesh Udpa	Ind. Non-Executive Director
Mrs. Shilpa Bung	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Godavari Drugs Ltd and is it undervalued?

As of 21 April 2026, Godavari Drugs Ltd's intrinsic value is ₹98.65, which is 6.30% higher than the current market price of ₹92.80, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (10.6 %), book value (₹60.3), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Godavari Drugs Ltd?

Godavari Drugs Ltd is trading at ₹92.80 as of 21 April 2026, with a FY2026-2027 high of ₹115 and low of ₹69.7. The stock is currently in the middle of its 52-week range. Market cap stands at ₹94.0 Cr..

How does Godavari Drugs Ltd's P/E ratio compare to its industry?

Godavari Drugs Ltd has a P/E ratio of 26.8, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Godavari Drugs Ltd financially healthy?

Key indicators for Godavari Drugs Ltd: ROCE of 10.1 % is moderate. Dividend yield is 0.00 %.

Is Godavari Drugs Ltd profitable and how is the profit trend?

Godavari Drugs Ltd reported a net profit of ₹4 Cr in Mar 2025 on revenue of ₹113 Cr. Compared to ₹5 Cr in Mar 2022, the net profit shows a declining trend.

Does Godavari Drugs Ltd pay dividends?

Godavari Drugs Ltd has a dividend yield of 0.00 % at the current price of ₹92.80. The company is currently not paying meaningful dividends.